Datamonitor Healthcare interviewed an endocrinologist based in the US and a rheumatologist based in the UK to gauge their views on current treatment options, late stage clinical candidates, treatment challenges and unmet needs in osteoporosis. The drugs discussed include abaloparatide (RDUS), Atelvia (AGN), Evenity (AMGN), Evista (LLY), Forteo (LLY), Fosamax (MRK), Prolia (AMGN) and Reclast (NVS). The two interviews were combined into a single report.

If you are a KOL Insight Subscriber, please access the first and second interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.